Cytokinetics CYTK License And Milestone Revenues — Deferred Revenue Current
Discontinued — last reported Q4 '24
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.
The official record: Cytokinetics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's license and milestone revenues — deferred revenue current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's license and milestone revenues — deferred revenue current?
- Cytokinetics (CYTK) reported license and milestone revenues — deferred revenue current of $52.4M in Q4 2024.
- What does license and milestone revenues — deferred revenue current mean?
- Payments received from partners for future services or milestones that have not yet been earned as revenue.
- How do you interpret license and milestone revenues — deferred revenue current?
- An increase suggests strong upfront payments from new or existing partnerships, signaling future revenue potential, while a decrease may indicate that the company is fulfilling its obligations faster than it is securing new contracts.
- How does license and milestone revenues — deferred revenue current compare across companies?
- Commonly referred to as 'Deferred Revenue' or 'Contract Liabilities' in the biotech industry, reflecting the pipeline of work owed to partners.